Tiziana Life Sciences Ltd
TLSA Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.87
KIRA · Stoqly’s AI analyst, in plain words
- Tiziana Life Sciences Ltd lost $18.4M in fiscal 2025.
- Free cash flow was −$12.9M in fiscal 2025, — of revenue.
Market cap
$103M
P/E
—
Revenue
—
Net income
−$18.4M
Free cash flow
−$12.9M
Operating margin
—
Tiziana Life Sciences Ltd in 30 seconds · fiscal 2025
Does it make a profit?
−$18.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Tiziana Life Sciences Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · May 1, 2026
- Legal name
- Tiziana Life Sciences Ltd
- CIK
- 0001723069
Tiziana Life Sciences Ltd · TLSA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$23.4M | −$15.4M | −$17.7M | −$11.9M | −$18.4M |
| Diluted EPS | −$0.24 | −$0.15 | −$0.17 | −$0.11 | −$0.16 |
| Cash | |||||
| Cash from operations | −$21.8M | −$19.6M | −$15.7M | −$1.5M | −$12.8M |
| Capital expenditure | $0.0M | — | — | $0.0M | $0.0M |
| Free cash flow | −$21.8M | — | — | −$1.5M | −$12.9M |
| Share count change | 0.6% | 3.7% | 0.9% | 4.1% | 10.9% |
| Debt and strength | |||||
| Cash and short-term investments | $42.2M | $18.1M | $1.2M | $3.7M | $4.0M |
| Shareholders' equity | $41.3M | $19.6M | $5.5M | $3.9M | $0.1M |
| Current ratio | 6.5x | 3.6x | 1.1x | 1.0x | 0.8x |
| Interest coverage | — | −16.7x | −43.7x | −8.9x | −1,174.0x |
| Returns and quality | |||||
| Return on equity | −45.2% | −50.6% | −140.9% | −250.5% | −924.3% |
| Return on tangible equity | −56.9% | −78.7% | −319.6% | −301.4% | −35,444.2% |
| Altman Z'' | 0.3 | −10.7 | −44.4 | −50.6 | −60.1 |
Insiders bought, 12 months
$1.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tiziana Life Sciences Ltd · TLSA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.87 a share, the company is worth $103M.
Source: SEC EDGAR XBRL filings (CIK 0001723069). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.